This phase II trial is to see if bevacizumab works in treating patients who have persistent or recurrent ovarian epithelial cancer or primary peritoneal cancer. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them.

No prior non-cytotoxic chemotherapy for recurrent or persistent disease

No concurrent chemotherapy directed at malignancy

At least 1 week since prior hormonal therapy directed at malignancy

No concurrent hormonal therapy directed at malignancy

Concurrent hormone replacement therapy allowed

Recovered from prior radiotherapy

No concurrent radiotherapy directed at malignancy

At least 28 days since prior major surgery or open biopsy and recovered

At least 7 days since prior core biopsy or placement of vascular access device

No anticipated need for major surgical procedure during study participation

At least 3 weeks since other prior therapy directed at malignancy

No prior anticancer therapy that would preclude study entry

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00022659